---

President and CEO, Vertex Pharmaceuticals

Reshma Kewalramani joined Vertex in 2017 as chief medical officer and executive vice president of global medicines development and medical affairs, becoming CEO in 2020. She has helped expand Vertex’ cystic fibrosis therapies pipeline, as well as its employee base and the number of medicines it offers.

Devoted to innovation in biomedicines and the fostering of new talent, Kewalramani also serves on Year Up’s national board of directors, the Biomedical Science Careers Program’s board of directors, the Massachusetts General Hospital board of trustees, and the Boston University Chobanian & Avedisian School of Medicine Dean’s Advisory Board. A Fellow of the American Society of Nephrology, she has a medical degree, with honors, from the Boston University Chobanian & Avedisian School of Medicine. Kewalramani is also an alumna of the Harvard Business School, from which she holds a Harvard Business School Alumni Achievement Award, and she also gained the Distinguished Alumni Award from the Boston University School of Medicine, among other honors, including the International Institute of New England Golden Door Award, the New England Council New Englander of the Year award, and the Asian American Business Development Center Pinnacle Award. She has been named one of Fortune’s Most Powerful Women, one of Boston Business Journal's “Power 50”, one of Boston magazine's most influential Bostonians, and one of Business Insider's “10 People Transforming Healthcare.”